Skip to main content
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · IEX Real-Time Price · USD
21.03
+0.13 (0.62%)
At close: Apr 26, 2024, 4:00 PM
21.49
+0.46 (2.19%)
After-hours: Apr 26, 2024, 4:26 PM EDT

Cartesian Therapeutics Revenue

In the year 2023, Cartesian Therapeutics had annual revenue of $26.00M, a decrease of -76.53%. Revenue in the quarter ending December 31, 2023 was $8.27M, a -50.78% decrease year-over-year.

Revenue (ttm)
$26.00M
Revenue Growth
-76.53%
P/S Ratio
14.38
Revenue / Employee
$702,811
Employees
37
Market Cap
373.91M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202326.00M-84.77M-76.53%
Dec 31, 2022110.78M25.70M30.21%
Dec 31, 202185.08M68.48M412.60%
Dec 31, 202016.60M9.92M148.57%
Dec 31, 20196.68M5.77M639.42%
Dec 31, 2018903.00K696.00K336.23%
Dec 31, 2017207.00K-7.88M-97.44%
Dec 31, 20168.08M2.07M34.47%
Dec 31, 20156.01M2.97M97.73%
Dec 31, 20143.04M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Amarin Corporation 306.91M
Zynex 184.32M
Anika Therapeutics 166.66M
Surmodics 138.20M
Harrow Health 130.19M
Heron Therapeutics 127.04M
ADC Therapeutics 69.56M
Aquestive Therapeutics 50.58M
Revenue Rankings

RNAC News

More News